Amalgamated Financial’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Amalgamated Financial’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$24K	Buy	+7,975	New	+$30K	﹤0.01%	2691

Other funds holding PRTK

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Amalgamated Financial's PRTK Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022: 7,975 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #2691 among its holdings.

100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Amalgamated Financial held 7,975 shares of Paratek Pharmaceuticals, Inc. worth $24K as of Q1 2022.
Paratek Pharmaceuticals, Inc. was a new Amalgamated Financial position in Q1 2022.
Paratek Pharmaceuticals, Inc. made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2691 holding.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.